Technology
Stabl-Im is TrivarX’s lead imaging development program, exploring novel approaches to understanding tumour biology.
MRI-Based Imaging Innovation
Advancing Precision Oncology
Non-Radioactive Stable Isotopes
Stabl-Im
Investigating Tumour Biology Without Ionising Radiation
Stabl-Im is an imaging-focused development program designed to explore whether stable isotope labelling can be used with MRI to generate additional information about tumour biology.
Scientific Rationale
The program is based on the rationale that tumour tissue, treatment-related change and normal tissue differ in cell turnover, water handling and microenvironmental characteristics.
By investigating these differences, Stabl-Im aims to assess whether stable isotope-informed MRI can support characterisation of active disease and treatment response.
Addressing an Unmet Need
MRI is already central to the diagnosis and monitoring of brain cancers and brain metastases. However, in some settings, differentiating active tumour from treatment-related changes or other tissue effects can remain challenging.
Complementary Imaging
Stabl-Im is being developed as a potential complementary imaging approach that may provide additional biological information alongside established imaging methods.
A Novel Imaging Approach
Unlike PET imaging, which uses radioactive tracers, Stabl-Im is designed to use non-radioactive isotopes that may be visualised using MRI-based methods.
Once clinically validated, this approach has the potential to support radiation-free molecular imaging research using infrastructure already available in many hospitals and imaging centres.
Non-Invasive Approach
Designed to investigate tumour biology without surgical sampling.
No Ionising Radiation
Uses stable isotopes. Intended to complement existing imaging modalities.
MRI-Based Methodology
Designed to leverage MRI infrastructure that is widely used in clinical care.
Tumour Monitoring Potential
May support assessment of tumour activity, disease progression and treatment response.
Precision Oncology Applications
Aims to provide biological information that may complement anatomical imaging findings.
Clinical Development
TrivarX is preparing Stabl-Im for first-in-human clinical evaluation.
Current development activities include supply, investigational product formulation and scale-up, analytical methodology work up, imaging methodology development, regulatory strategy and finalisation of clinical study design.
The planned clinical trial to begin H2 CY26 is intended to evaluate safety, feasibility, imaging performance and reproducibility in patients with brain tumours or brain metastases.
Data generated from the study are expected to inform further clinical development, including multi-centre studies and broader clinical applications.
